

RECEIVED
CENTRAL FAX CENTER

MAY 11 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ofer BINAH et al. Confirmation No.: 2981
Application No.: 10/761,528 Group Art Unit: 1642
Filing Date: January 20, 2004 Examiner:
For: ANTI-TUMOR ACTIVITY FROM REPTILE SERUM Attorney Docket No.: 85189-6000

REQUEST FOR CORRECTION OF FILING RECEIPT

Office of Initial Patent Examination
Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A Filing Receipt for the above-identified application has been received and the following corrections are respectfully requested.

Please add the Domestic Priority data as follows:

-- This application is a CON of PCT/IL02/00590 07/18/2002 --.


Support for this change is found in the specification and in the published application, copies of the appropriate pages of which are attached hereto.

A marked-up copy of the Filing Receipt with the requested change noted thereon is attached. Please issue a corrected Filing Receipt in due course.

No fee is believed to be due for this submission. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814.

Respectfully submitted,

May 10, 2005
Date


E. Bradley Gould (Reg. No. 41,792)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN LLP
Customer No. 28765
202-282-5771

DCI416060.1



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22312-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/761,528	01/20/2004	1642	1058	85189-8000	25	35	14

28765
WINSTON & STRAWN
PATENT DEPARTMENT
1400 L STREET, N.W.
WASHINGTON, DC 20005-3502

CONFIRMATION NO. 2981
UPDATED FILING RECEIPT
OC000000013709634
OC000000013709634

Date Mailed: 09/03/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ofer Binah, Noft, ISRAEL;
Aaron Ciechanover, Haifa, ISRAEL;
Gila Maor, Kiriath Motzkin, ISRAEL;

Power of Attorney:

Allan A. Fenucci-30256
Daniel Hulseberg-36554
Jeffrey Wolfson-42234

Domestic Priority date as claimed by applicant

This application is a CON of PCT/IL02/00590 07/18/2002
Foreign Applications

ISRAEL IL 144447 07/19/2001

If Required, Foreign Filing License Granted: 04/23/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/761,528

Projected Publication Date: 12/09/2004

Non-Publication Request: No

Early Publication Request: No

" SMALL ENTITY "

Title

Anti-tumor activity from reptile serum

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).